Opaleye Management Inc. recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
9B Russell Street Cambridge, MA 02140
As of the latest 13F report, the guru’s equity portfolio contained 40 stocks valued at a total of $288.00Mil. The top holdings were HROW(19.38%), TELA(8.29%), and RYTM(7.44%).
According to GuruFocus data, these were Opaleye Management Inc.’s top five trades of the quarter.
Cutera Inc
The guru sold out of their 147,700-share investment in NAS:CUTR. Previously, the stock had a 2.78% weight in the equity portfolio. Shares traded for an average price of $45.6 during the quarter.
On 02/13/2023, Cutera Inc traded for a price of $35 per share and a market cap of $686.54Mil. The stock has returned -7.38% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Cutera Inc has a price-book ratio of 44.30, a EV-to-Ebitda ratio of -10.85 and a price-sales ratio of 2.61.
The price-to-GF Value ratio is 0.80, earning the stock a GF Value rank of 9.
Biohaven Ltd
The guru established a new position worth 540,000 shares in NYSE:BHVN, giving the stock a 2.61% weight in the equity portfolio. Shares traded for an average price of $14.12 during the quarter.
On 02/13/2023, Biohaven Ltd traded for a price of $16.98 per share and a market cap of $1.16Bil. The stock has returned 0.00% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Biohaven Ltd has a price-book ratio of 6.07 and a EV-to-Ebitda ratio of -9.42.
Harrow Health Inc
During the quarter, Opaleye Management Inc. bought 431,183 shares of NAS:HROW for a total holding of 3,775,000. The trade had a 2.21% impact on the equity portfolio. During the quarter, the stock traded for an average price of $11.95.
On 02/13/2023, Harrow Health Inc traded for a price of $18.62 per share and a market cap of $554.69Mil. The stock has returned 125.70% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Harrow Health Inc has a price-book ratio of 413.78, a EV-to-Ebitda ratio of 228.74 and a price-sales ratio of 5.74.
The price-to-GF Value ratio is 1.57, earning the stock a GF Value rank of 1.
KalVista Pharmaceuticals Inc
The guru established a new position worth 923,200 shares in NAS:KALV, giving the stock a 2.17% weight in the equity portfolio. Shares traded for an average price of $5.36 during the quarter.
On 02/13/2023, KalVista Pharmaceuticals Inc traded for a price of $7.96 per share and a market cap of $271.46Mil. The stock has returned -47.32% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, KalVista Pharmaceuticals Inc has a price-book ratio of 1.36 and a EV-to-Ebitda ratio of -1.50.
The price-to-GF Value ratio is 2.93, earning the stock a GF Value rank of 1.
Inhibrx Inc
The guru sold out of their 292,700-share investment in NAS:INBX. Previously, the stock had a 2.17% weight in the equity portfolio. Shares traded for an average price of $29.39 during the quarter.
On 02/13/2023, Inhibrx Inc traded for a price of $23.1 per share and a market cap of $1.01Bil. The stock has returned -5.13% over the past year.
GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Inhibrx Inc has a EV-to-Ebitda ratio of -9.28 and a price-sales ratio of 190.91.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
